Physician profile
Daniel B Rancier
NPI 1558364885
$11,728.10
in general payments reported to CMS, 2019-2025
44 companies · $1,835 in 2025
The $1,835 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,340 · 2020: $1,164 · 2021: $1,626 · 2022: $1,880 · 2023: $2,424 · 2024: $1,459 · 2025: $1,835.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,718.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,718.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,663.32 | 2019-2025 | Trelegy Ellipta, Shingrix |
| Astrazeneca Pharmaceuticals LP | $1,353.28 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $1,300.06 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $971.75 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Abbvie INC. | $909.16 | 2019-2025 | |
| Pfizer INC. | $692.43 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $634.65 | 2019-2025 | Jardiance, Spiriva Respimat, Stiolto Respimat |
| Bayer Healthcare Pharmaceuticals INC. | $586.47 | 2021-2025 | |
| Sanofi-Aventis U.S. LLC | $439.11 | 2019-2023 | |
| Shield Therapeutics INC | $314.08 | 2023-2025 | Accrufer |
| Merck Sharp & Dohme LLC | $275.81 | 2019-2025 | Gardasil 9, Vaxelis, Vaxneuvance |
| Axsome Therapeutics, INC. | $274.17 | 2023-2025 | Auvelity, Sunosi |
| Amarin Pharma, INC. | $238.30 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $225.09 | 2022-2024 | Rexulti, Nuedexta |
| Exact Sciences Corporation | $160.84 | 2023-2025 | Cologuard Collection Kit |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Rancier listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.